started · updated
Singapore Court of Appeal upholds asset freezing order in Novo Nordisk dispute
The Singapore Court of Appeal has upheld a decision by the Singapore International Commercial Court to maintain a worldwide freezing order in support of an arbitration seated in New York. The case, KBP Biosciences Pte Ltd v Novo Nordisk A/S, involves a dispute over the acquisition of rights to the drug Ocedurenone.
Novo Nordisk, a Danish pharmaceutical company, entered into an asset purchase agreement with Singaporean firm KBP Biosciences in October 2023. The deal involved a USD 700 million payment and a USD 100 million escrow deposit. The dispute arose following the failure of Phase 3 clinical trials for the drug.
Novo Nordisk alleges that KBP Biosciences and its founder, Dr. Huang Zhenhua, withheld material information regarding earlier clinical trial results, specifically concerning anomalies at a trial site in Bulgaria. The company has advanced claims involving alleged fraudulent breaches of warranty and misrepresentations.
Entities
Dr. Huang Zhenhua · International Chamber of Commerce · KBP Biosciences Pte Ltd · Novo Nordisk A/S · Singapore Court of Appeal